(Q40185773)

18 September 2017

title

Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances (English)

1 reference

18 September 2017

Kazuhiro Nouso

1

1 reference

18 September 2017

Hironori Tanaka

2

1 reference

18 September 2017

Shuji Uematsu

3

1 reference

18 September 2017

Kunihiro Shiraga

4

1 reference

18 September 2017

Ryoichi Okamoto

5

1 reference

18 September 2017

Hideki Onishi

6

1 reference

18 September 2017

Shin-Ichiro Nakamura

7

1 reference

18 September 2017

Yoshiyuki Kobayashi

8

1 reference

18 September 2017

Yasuyuki Araki

9

1 reference

18 September 2017

Noriaki Aoki

10

1 reference

18 September 2017

Yasushi Shiratori

11

1 reference

18 September 2017

publication date

6 August 2007

1 reference

Journal of Gastroenterology and Hepatology

18 September 2017

published in

1 reference

18 September 2017

volume

23

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

437-444

1 reference

18 September 2017

cites work

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Screening in liver disease: report of an AASLD clinical workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Screening for hepatocellular carcinoma in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Survival and prognostic indicators in compensated and decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Cost-effectiveness of percutaneous radiofrequency ablation for malignant hepatic neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Hepatocellular carcinoma and hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Risk factors for hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Clinical features, etiology, and survival of hepatocellular carcinoma among different countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Compensated cirrhosis: Natural history and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05054.X

10.1111/J.1440-1746.2007.05054.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference